Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors

James R. Hands, Peter Abel, Katherine Ashton, Timothy Dawson, Charles Davis, Robert W. Lea, Alastair J S McIntosh, Matthew J. Baker

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The ability to diagnose brain cancer rapidly from serum samples is of great interest; such a diagnosis would allow for rapid testing and time to results providing a responsive diagnostic environment, ability to monitor treatment efficacy, early detection of recurrent tumours and screening techniques. Current methods rely upon subjective, time-consuming tests such as histological grading and are particularly invasive with the diagnostic test requiring hospitalisation of 2-3 days. A rapid diagnostic method based upon serum samples would allow for a relatively non-invasive test and open up the possibility of screening for brain cancer. We report for the first time the use of a Bioplex immunoassay to provide cytokine and angiogenesis factor levels that differ between serum from glioma and non-cancer patients specifically angiopoietin, follistatin, HGF, IL-8, leptin, PDGF-BB and PECAM-1 providing sensitivities and specificities as high as 88 % and 81 %, respectively. We also report, for the first time, the use of serum ATR-FTIR combined with a RBF SVM for the diagnosis of gliomas from non-cancer patients with sensitivities and specificities as high as 87.5 % and 100 %, respectively. We describe the combination of these techniques in an orthogonal diagnostic regime, providing strength to the diagnosis through data combinations, in a rapid diagnostic test within 5 h from serum collection (10 min for ATR-FTIR and 4 h for the Bioplex Immunoassay). This regime has the ability to revolutionise the clinical environment by providing objective measures for diagnosis allowing for increased efficiency with corresponding decreases in mortality, morbidity and economic impact upon the health services. [Figure not available: see fulltext.]

LanguageEnglish
Pages7347-7355
Number of pages9
JournalAnalytical and Bioanalytical Chemistry
Volume405
Issue number23
DOIs
Publication statusPublished - 1 Sep 2013

Fingerprint

Angiogenesis Inducing Agents
Glioma
Infrared spectroscopy
Spectrum Analysis
Cytokines
Serum
Fourier Transform Infrared Spectroscopy
Immunoassay
Routine Diagnostic Tests
Brain Neoplasms
Brain
Screening
Angiopoietins
Follistatin
CD31 Antigens
Sensitivity and Specificity
Leptin
Interleukin-8
Health Services
Tumors

Keywords

  • angiogenesis
  • cytokines
  • glioma
  • infrared
  • orthogonal
  • rapid

Cite this

Hands, James R. ; Abel, Peter ; Ashton, Katherine ; Dawson, Timothy ; Davis, Charles ; Lea, Robert W. ; McIntosh, Alastair J S ; Baker, Matthew J. / Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors. In: Analytical and Bioanalytical Chemistry. 2013 ; Vol. 405, No. 23. pp. 7347-7355.
@article{6a5a8e3049754e029e537ae4f6a0513f,
title = "Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors",
abstract = "The ability to diagnose brain cancer rapidly from serum samples is of great interest; such a diagnosis would allow for rapid testing and time to results providing a responsive diagnostic environment, ability to monitor treatment efficacy, early detection of recurrent tumours and screening techniques. Current methods rely upon subjective, time-consuming tests such as histological grading and are particularly invasive with the diagnostic test requiring hospitalisation of 2-3 days. A rapid diagnostic method based upon serum samples would allow for a relatively non-invasive test and open up the possibility of screening for brain cancer. We report for the first time the use of a Bioplex immunoassay to provide cytokine and angiogenesis factor levels that differ between serum from glioma and non-cancer patients specifically angiopoietin, follistatin, HGF, IL-8, leptin, PDGF-BB and PECAM-1 providing sensitivities and specificities as high as 88 {\%} and 81 {\%}, respectively. We also report, for the first time, the use of serum ATR-FTIR combined with a RBF SVM for the diagnosis of gliomas from non-cancer patients with sensitivities and specificities as high as 87.5 {\%} and 100 {\%}, respectively. We describe the combination of these techniques in an orthogonal diagnostic regime, providing strength to the diagnosis through data combinations, in a rapid diagnostic test within 5 h from serum collection (10 min for ATR-FTIR and 4 h for the Bioplex Immunoassay). This regime has the ability to revolutionise the clinical environment by providing objective measures for diagnosis allowing for increased efficiency with corresponding decreases in mortality, morbidity and economic impact upon the health services. [Figure not available: see fulltext.]",
keywords = "angiogenesis, cytokines, glioma, infrared, orthogonal, rapid",
author = "Hands, {James R.} and Peter Abel and Katherine Ashton and Timothy Dawson and Charles Davis and Lea, {Robert W.} and McIntosh, {Alastair J S} and Baker, {Matthew J.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1007/s00216-013-7163-z",
language = "English",
volume = "405",
pages = "7347--7355",
journal = "Analytical and Bioanalytical Chemistry",
issn = "1618-2642",
number = "23",

}

Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors. / Hands, James R.; Abel, Peter; Ashton, Katherine; Dawson, Timothy; Davis, Charles; Lea, Robert W.; McIntosh, Alastair J S; Baker, Matthew J.

In: Analytical and Bioanalytical Chemistry, Vol. 405, No. 23, 01.09.2013, p. 7347-7355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Investigating the rapid diagnosis of gliomas from serum samples using infrared spectroscopy and cytokine and angiogenesis factors

AU - Hands, James R.

AU - Abel, Peter

AU - Ashton, Katherine

AU - Dawson, Timothy

AU - Davis, Charles

AU - Lea, Robert W.

AU - McIntosh, Alastair J S

AU - Baker, Matthew J.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - The ability to diagnose brain cancer rapidly from serum samples is of great interest; such a diagnosis would allow for rapid testing and time to results providing a responsive diagnostic environment, ability to monitor treatment efficacy, early detection of recurrent tumours and screening techniques. Current methods rely upon subjective, time-consuming tests such as histological grading and are particularly invasive with the diagnostic test requiring hospitalisation of 2-3 days. A rapid diagnostic method based upon serum samples would allow for a relatively non-invasive test and open up the possibility of screening for brain cancer. We report for the first time the use of a Bioplex immunoassay to provide cytokine and angiogenesis factor levels that differ between serum from glioma and non-cancer patients specifically angiopoietin, follistatin, HGF, IL-8, leptin, PDGF-BB and PECAM-1 providing sensitivities and specificities as high as 88 % and 81 %, respectively. We also report, for the first time, the use of serum ATR-FTIR combined with a RBF SVM for the diagnosis of gliomas from non-cancer patients with sensitivities and specificities as high as 87.5 % and 100 %, respectively. We describe the combination of these techniques in an orthogonal diagnostic regime, providing strength to the diagnosis through data combinations, in a rapid diagnostic test within 5 h from serum collection (10 min for ATR-FTIR and 4 h for the Bioplex Immunoassay). This regime has the ability to revolutionise the clinical environment by providing objective measures for diagnosis allowing for increased efficiency with corresponding decreases in mortality, morbidity and economic impact upon the health services. [Figure not available: see fulltext.]

AB - The ability to diagnose brain cancer rapidly from serum samples is of great interest; such a diagnosis would allow for rapid testing and time to results providing a responsive diagnostic environment, ability to monitor treatment efficacy, early detection of recurrent tumours and screening techniques. Current methods rely upon subjective, time-consuming tests such as histological grading and are particularly invasive with the diagnostic test requiring hospitalisation of 2-3 days. A rapid diagnostic method based upon serum samples would allow for a relatively non-invasive test and open up the possibility of screening for brain cancer. We report for the first time the use of a Bioplex immunoassay to provide cytokine and angiogenesis factor levels that differ between serum from glioma and non-cancer patients specifically angiopoietin, follistatin, HGF, IL-8, leptin, PDGF-BB and PECAM-1 providing sensitivities and specificities as high as 88 % and 81 %, respectively. We also report, for the first time, the use of serum ATR-FTIR combined with a RBF SVM for the diagnosis of gliomas from non-cancer patients with sensitivities and specificities as high as 87.5 % and 100 %, respectively. We describe the combination of these techniques in an orthogonal diagnostic regime, providing strength to the diagnosis through data combinations, in a rapid diagnostic test within 5 h from serum collection (10 min for ATR-FTIR and 4 h for the Bioplex Immunoassay). This regime has the ability to revolutionise the clinical environment by providing objective measures for diagnosis allowing for increased efficiency with corresponding decreases in mortality, morbidity and economic impact upon the health services. [Figure not available: see fulltext.]

KW - angiogenesis

KW - cytokines

KW - glioma

KW - infrared

KW - orthogonal

KW - rapid

UR - http://www.scopus.com/inward/record.url?scp=84883556314&partnerID=8YFLogxK

U2 - 10.1007/s00216-013-7163-z

DO - 10.1007/s00216-013-7163-z

M3 - Article

VL - 405

SP - 7347

EP - 7355

JO - Analytical and Bioanalytical Chemistry

T2 - Analytical and Bioanalytical Chemistry

JF - Analytical and Bioanalytical Chemistry

SN - 1618-2642

IS - 23

ER -